GLP3-RT+20.png
GLP3 RT 10MG COA.jpg
GLP3-RT+20.png
GLP3 RT 10MG COA.jpg

GLP3 RT 20mg

$220.00

RUO=Research use only

The benefits of “GLP‑3,” more accurately known as retatrutide, are striking in clinical trials and suggest it could be a powerful tool for treating obesity and metabolic disease. Participants have experienced up to 24% reductions in body weight, which is greater than what has been seen with current GLP‑1 or dual agonist drugs. Beyond weight loss, retatrutide has improved blood sugar control by lowering HbA1c levels, enhanced insulin sensitivity, and reduced liver fat by as much as 82%, making it promising for conditions like type 2 diabetes and fatty liver disease. It has also shown cardiometabolic improvements, including lower blood pressure, cholesterol, and waist circumference, while increasing energy expenditure through glucagon receptor activation. Taken together, these effects point to broad potential applications in obesity, diabetes, and metabolic syndrome, with the added possibility of reducing long‑term cardiovascular risk.

RUO=Research use only

The benefits of “GLP‑3,” more accurately known as retatrutide, are striking in clinical trials and suggest it could be a powerful tool for treating obesity and metabolic disease. Participants have experienced up to 24% reductions in body weight, which is greater than what has been seen with current GLP‑1 or dual agonist drugs. Beyond weight loss, retatrutide has improved blood sugar control by lowering HbA1c levels, enhanced insulin sensitivity, and reduced liver fat by as much as 82%, making it promising for conditions like type 2 diabetes and fatty liver disease. It has also shown cardiometabolic improvements, including lower blood pressure, cholesterol, and waist circumference, while increasing energy expenditure through glucagon receptor activation. Taken together, these effects point to broad potential applications in obesity, diabetes, and metabolic syndrome, with the added possibility of reducing long‑term cardiovascular risk.

Rigorous Third-Party Testing

Every batch of our research chemicals and peptides undergoes third-party testing. 

So Cal Bioresearch is a chemical supplier. So Cal Bioresearch is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act. So Cal Bioresearch is not an outsourcing facility as defined under Section 503B of the Federal Food, Drug, and Cosmetic Act. All products are sold solely for research, laboratory, or analytical purposes and are not intended for human consumption. 

*Product is sold as a lyophilized powder

  • Due to recent inconsistency with ground shipping all peptides are shipping priority for reliability.